Carolyn Lam, MD, PhD
Professor, Duke-National University of Singapore
Senior Consultant, Department of Cardiology and Director of Women’s Heart Health
National Heart Centre Singapore
This lecture traces the development of understanding HFpEF and its treatment over the years; and what are the current and future management of HFpEF.
At the conclusion of the activity a participant should be able to:
- Describe the evolution of nomenclature and mechanistic understanding of HFpEF
- Review treatment approaches that have and have not worked in HFpEF
- Explain recent developments and their implications for future management of HFpEF
Carolyn Lam, MD, PhD is a consultant or on the advisory board for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai. She receives research grant support for Bayer and Roche Diagnostics. She is also co-founder and non-executive director forf US2.ai.
The Planning Committee has nothing to disclose relevant to this program.
The THI CME Staff has nothing to disclose relevant to this program.
The Program Reviewers has nothing to disclose relevant to this program.
All relevant financial relationships have been mitigated.
Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Texas Heart Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.